Biocon is actively pursuing in-licensing opportunities to expand its biosimilars portfolio as part of a strategic shift aimed at leveraging its growing global commercial presence, Managing Director and Chief Executive Officer Shreehas Tambe said Thursday. The company seeks to strengthen its existing therapy franchises through disciplined product acquisitions that complement, rather than create entirely new markets.

Tambe highlighted etanercept as an example of Biocon’s in-licensing approach, noting that while the company did not develop the product internally, acquiring it helped complete its portfolio and align with its commercial strategy. This approach reflects Biocon’s broader transition in the 2026-27 financial year (FY27) from a “preserve” phase, characterized by major investments, to a “consolidate” phase focused on maximizing capacity utilization, expanding profit margins, and improving return on capital employed.

The company anticipates a multi-product launch cycle to drive revenue growth during FY27, with a particular impact expected in the second half. Biocon plans to introduce five biosimilars in the United States over the next year. Among current offerings, Yesintek, the company’s biosimilar to Stelara, has captured nearly 20 percent market share. Recent launches of denosumab biosimilars have bolstered Biocon’s oncology and bone health segments. Additionally, insulin aspart, marketed as Kirsty, has been introduced within closed-door networks and is slated to expand into commercial payer channels later in the year.

Two further biosimilars, aflibercept branded Yesafili and bevacizumab, are projected to enter the U.S. market and contribute to sales growth in the latter half of FY27. Tambe emphasized that while driving top-line growth and gaining market share remain priorities, the company also aims to maintain sustainable margins and achieve profitable expansion.

On profitability, Biocon’s biosimilar business reported an earnings before interest, taxes, depreciation, and amortization (EBITDA) margin of 26 percent in the fourth quarter of FY26, matching the full-year margin and marking a 40 percent increase on a like-for-like basis compared to previous periods. The company’s efforts to enhance its biosimilars portfolio through strategic in-licensing and product launches underscore its focus on consolidating gains and improving capital efficiency moving forward.